Johnson & Johnson sells prescription medicines, such as Darzalex for blood cancer and Tremfya, and medical devices for heart, eye and joint care. Medicines were $16.8 billion of its $25.4 billion of sales in the third quarter of 2026. It plans to spin off its joint and bone business as a separate company called DePuy Synthes.
Johnson & JohnsonPrescription medicines plus medical devices
J&J earns from
J&J depends on1 of 7
Genmab
Size$4.24 billion of Darzalex sales (Q3 2026)
Genmab, a Danish biotech, gave J&J the worldwide rights to the cancer drug Darzalex and receives royalties on its sales. Darzalex sold $4.24 billion in the third quarter of 2026.
Boxes with a corner arrow have their own map. Sizes show where a source gives one.
Outside forces
Things Johnson & Johnson can't control that affect its business. Tap one to see what to watch.
Talc lawsuitsIn July 2026 J&J proposed paying $5.5 billion to settle about 76,000 lawsuits claiming its talc powder caused ovarian cancer. The deal needs at least 95% of claimants to join, and a one-time charge for it cut third-quarter earnings.What to watch
Orthopaedics spin-offJ&J plans to make its joint replacement and trauma business a separate company called DePuy Synthes, announced in October 2025 for completion within 18 to 24 months.What to watch
Stelara copiesStelara faces copies known as biosimilars. Its sales fell 41% to $6.1 billion in 2025, and the decline cut third-quarter 2026 growth by about 6.9 points.What to watch
How fast newer drugs such as Tremfya and Icotyde fill the gap.
A one-time charge for the proposed talc settlement, plus costs from buying Firefly Bio and the Sail Biomedicines deal, in the third quarter of 2026. Earnings were $2.12 a share a year earlier.
What is DePuy Synthes?
J&J's orthopaedics business, which makes hip, knee and other implants. J&J plans to spin it off as a separate company.
Does J&J own Darzalex?
J&J sells it under a worldwide license from Genmab, which receives royalties on the sales.
Read every connection
All 7 connections as cards, with sources. It's the same detail you get by tapping a box on the map.Show allHide
Suppliers
The companies Johnson & Johnson relies on to make what it sells, with sources.
Genmab
Licensed it Darzalex
Size$4.24 billion of Darzalex sales (Q3 2026)
Genmab, a Danish biotech, gave J&J the worldwide rights to the cancer drug Darzalex and receives royalties on its sales. Darzalex sold $4.24 billion in the third quarter of 2026.
J&J and Legend Biotech sell Carvykti, a cell therapy for the blood cancer multiple myeloma, together. Its sales rose 36% to about $710 million in the third quarter of 2026.
What to watch: Use in earlier stages of the disease, now half of US volume.
J&J and Protagonist jointly discovered Icotyde, a daily pill for psoriasis approved by the FDA in March 2026. J&J sells it and pays Protagonist 6% to 10% royalties.
What to watch: How quickly the pill wins patients from injected drugs.
In July 2026 J&J paid about $785 million to start a partnership with Sail, including a $465 million stake, on cell therapies for immune diseases. It has an option to buy Sail for about $2.6 billion.
J&J bought Firefly Bio for $1 billion in cash in July 2026 for its technology that delivers drugs into hard-to-treat cancer cells. The deal was booked as a charge of about $1 billion.
What to watch: Progress of the cancer programs it gained.
Who buys from Johnson & Johnson or pays it, with sources.
Patients and drug plans
Innovative Medicine
Size$16.76 billion (Q3 2026)
Medicine sales rose 7.7% to $16.76 billion in the third quarter of 2026, helped by Tremfya, Darzalex and Carvykti. Falling sales of Stelara, which now faces copies, cut growth by about 6.9 points.
What to watch: Stelara's decline against new medicines.
Device sales were $8.64 billion in the third quarter of 2026, up 2.5%. Heart devices, including Shockwave, and contact lenses grew, while the chief executive said MedTech fell short of what the company wanted.
Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.
How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.